Carl L. Gordon Buys 47,502 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon acquired 47,502 shares of MBX Biosciences stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $9.87 per share, with a total value of $468,844.74. Following the completion of the acquisition, the director now owns 3,205,930 shares of the company's stock, valued at $31,642,529.10. The trade was a 1.50 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

MBX Biosciences Stock Performance

MBX stock traded down $0.84 during midday trading on Friday, hitting $11.00. 86,797 shares of the stock were exchanged, compared to its average volume of 308,918. MBX Biosciences, Inc. has a fifty-two week low of $8.63 and a fifty-two week high of $27.50. The stock's 50-day moving average is $14.05.

Institutional Trading of MBX Biosciences

A number of large investors have recently made changes to their positions in MBX. The Manufacturers Life Insurance Company acquired a new stake in shares of MBX Biosciences during the third quarter valued at $1,200,000. NEA Management Company LLC acquired a new stake in shares of MBX Biosciences during the third quarter valued at $93,904,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of MBX Biosciences during the third quarter valued at $278,000. Maven Securities LTD purchased a new position in MBX Biosciences during the third quarter worth about $1,299,000. Finally, Point72 Asset Management L.P. purchased a new position in MBX Biosciences during the third quarter worth about $405,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.